Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: Relationship to proliferative activity and prognostic significance

Medical Oncology

Volumn 21, Issue 1, 2004, Pages 73-79

  Markovic, O ^a,d   Marisavljevic, D ^a   Cemerikic, V ^b   Suvajdzic, N ^b   Milic, N ^c   Colovic, M ^b  

^a Medical Centre   (Yugoslavia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d Auto Put bb   (Yugoslavia)

Author keywords

Cyclin D1; Immunohistochemistry; Ki 67; Multiple myeloma; p53

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; CYCLIN D1; HEMOGLOBIN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PARAFFIN; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; THROMBOCYTE COUNT;

EID: 1842855272     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:21:1:73     Document Type: Article

References (22)

1. Pratt G. Molecular aspects of multiple meloma. Mol Pathol 2002;55:273-283.
2. Hallek M, Bergsagel PI, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998;91(1):3-21.
3. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
4. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors some of age. Cell 1994;79(4):573-582.
5. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-528.
6. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88(3):323-331.
7. Chronic Leukemia-Myeloma Task Force. Guidelines for protocol studies. Cancer Chem Rep 1973;4:145-153.
8. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842-854.
9. Sailer M, Vykoupil KF, Peest D, Coldewey R, Deicher H, Georgii A. Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: A histopathological evaluation of biopsies from 153 untreated patients. Eur J Haematol 1995;54:137-146.
10. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 1987;87:342-355.
11. Vasef MA, Medeiros LJ, Yospur LS, Sun NC, McCourty A, Brynes RK. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol 1997;10(9):927-932.
12. waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Mod Pathol 1998;11(7):642-647.
13. Pruneri G, et al. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol 2000;156:1505-1513.
14. Athanasiou E, et al. Cyclin D1 overexpresion in multiple myeloma. A morphologic, immunohistochemical and in situ hibridization study of 71 paraffin-embedded bone marrow biopsy specimens. Am J Clin Pathol 2001;116(4):535-542.
15. Hoechtlen-Vollmar W, Menzel G, Bartl R, Lamerz R, Wick M, Seidel D. Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. Br J Haematol 2000;109:30-38.
16. Rasmussen T, Knudsen LM, Johnsen HE. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma. Eur J Haematol 2001;67:296-301.
17. Sonoki T, et al. Expresion of PRAD1/cyclin D1 in plasma cell malignancy: incidence and prognostic aspects. Br J Haematol 1999;104:614-617.
18. Wilson CS, et al. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalitis and DNA ploidy. Br J Haematology 2001;112:776-782.
19. Hinds PW, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Different 1990;1(12):571-580.
20. Neri A, Baldini L, Trecca L, Cro L, Polli E, Maiolo AT. p53 gene mutations in m ultiple myeloma are associated with advanced forms of malignancy. Blood 1993;81(1):128-135.
21. Ollikainen H, Syrjanen S, Koskela K, Pelliniemi TT, Pulkki K. p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma. Scand J Clin Lab Invest 1997;57(4):281-289.
22. Preudhomme C, et al. Rare occurrence of p53 gene mutations in multiple myeloma. Br J Haematol 1992;81(3):440-443.